PPCB ▲ +7.9% - Propanc Biopharma, Inc. $PPCB - Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 Propanc Biopharma rose 7.9% today following the company's presentation of differentiated data for its PRP pancreatic cancer treatment compared to the emerging pan-RAS program ERAS-0015. The positive clinical comparison appears to have boosted investor confidence in Propanc's competitive positioning in the pancreatic cancer space. 22-SEP-2026 08:30 AM ET